We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Regulatory News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Dec 2019 09:00



Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS
 
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ0
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rights 
Other (please specify)iii: 
3. Details of person subject to the notification obligationiv
NameRobert W. Duggan
City and country of registered office (if applicable) 
4. Full name of shareholder(s) (if different from 3.)v
NameRobert W. Duggan
City and country of registered office (if applicable) 
5. Date on which the threshold was crossed or reachedvi:24/12/2019
6. Date on which issuer notified (DD/MM/YYYY):30/12/2019
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached49.47%23.31%72.78%335,873,208
Position of previous notification (if applicable)n/a48.78%48.78% 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of sharesISIN code (if possible)Number of voting rightsix% of voting rights
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01166,157,050 49.47% 
SUBTOTAL 8. A166,157,05049.47%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
American Depositary Shares (ADS)n/an/a78,288,20523.31%
  SUBTOTAL 8. B 178,288,20523.31%
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights
      
   SUBTOTAL 8.B.2  

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiiiX
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) 
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
    
    
    
    
    
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional informationxvi
 

Place of completionFlorida, United States of America
Date of completion30/12/2019


Date   Source Headline
17th Feb 20205:30 pmRNSSummit Therapeutics
11th Feb 202010:00 amGNWAIM Delisting Reminder
10th Feb 20202:15 pmGNWDirector/PDMR Shareholding
6th Feb 202012:00 pmGNWSummit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma
4th Feb 202012:00 pmGNWSummit Therapeutics to Present at the 2020 BIO CEO & Investor Conference
27th Jan 20207:00 amGNWExercise of Restricted Stock Units
24th Jan 202012:00 pmGNWSummit Announces Management Update
23rd Jan 202012:00 pmGNWSummit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work
20th Jan 20202:15 pmGNWHolding(s) in Company
20th Jan 20202:15 pmGNWHolding(s) in Company
15th Jan 202012:15 pmGNWNotification of Transactions of Persons Discharging Managerial Responsibilities
7th Jan 202012:00 pmGNWSummit Therapeutics Launches Online Resource for Patients with C. difficile Infection
31st Dec 20199:00 amGNWHolding(s) in Company
30th Dec 20197:00 amGNWHolding(s) in Company
24th Dec 20198:30 amGNWCompletion of $50 million Fundraising and Directorate Change
24th Dec 20197:01 amGNWAward of Share Options
24th Dec 20197:00 amGNWExercise of Restricted Stock Units
23rd Dec 201912:00 pmGNWResult of General Meeting
19th Dec 20197:00 amGNWTimetable Update
17th Dec 201912:00 pmGNWSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019
16th Dec 20192:15 pmGNWNotice of Q3 Results
6th Dec 201912:00 pmGNWSummit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
6th Nov 201912:00 pmGNWSummit Therapeutics to Participate in Panel Sessions at the World Antimicrobial Resistance Congress
4th Nov 201912:00 pmGNWSummit Therapeutics Recognises C. difficile Awareness Month
16th Oct 201912:00 pmGNWSummit Therapeutics to Present at the 2019 BIO Investor Forum
11th Oct 201912:01 pmGNWDirectorate change
11th Oct 201912:00 pmGNWHalf-year report
10th Oct 20192:30 pmGNWNotice of Results
7th Oct 201912:00 pmGNWSummit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
3rd Oct 201912:00 pmGNWSummit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
3rd Oct 20197:00 amGNWBlock Listing Six Month Review
1st Oct 20192:05 pmRNSSecond Price Monitoring Extn
1st Oct 20192:00 pmRNSPrice Monitoring Extension
25th Sep 201912:00 pmGNWSummit Therapeutics to Host R&D Day 7 October 2019
24th Sep 201912:00 pmGNWSummit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
18th Sep 20197:00 amGNWSummit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
5th Sep 201912:00 pmGNWSummit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
4th Sep 201912:00 pmGNWSummit Therapeutics to Participate in Upcoming Investor Conferences
1st Aug 201912:00 pmGNWSummit Therapeutics to Present at the Canaccord Genuity Growth Conference
17th Jul 201912:00 pmGNWSummit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
9th Jul 201912:00 pmGNWSummit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20th Jun 201912:00 pmGNWSummit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19th Jun 201912:00 pmGNWResult of AGM
18th Jun 201912:00 pmGNWIncreased BARDA Award and Option Exercise
12th Jun 201912:00 pmGNWSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
5th Jun 20192:00 pmGNWNotice of First Quarter Results
14th May 20195:30 pmGNWUK Annual Report and Notice of AGM
29th Apr 201912:30 pmGNWBlock Listing Interim Review
24th Apr 20194:20 pmGNWExercise of Restricted Stock Units
15th Apr 20197:00 amGNWSummit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.